Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors

Inclusion Criteria: * Ability to understand and willingness to sign a written informed consent document. * Age 18 and older. * Confirmed unresectable or metastatic refractory cancer with measurable disease per RECIST (version 1.1) (i.e. at least 1 lesion \> 1 cm or lymph node \> 1.5 cm in short axis). * Progressive disease after multiple-lines treatment. * Completion of entry into 68Ga-FAPI-46 study and completion of scan. The tumor lesions showing increased radiotracer uptake on 68Ga-FAPI-46 PET/CT (defined as a maximum standardized uptake value ≥10 in more than 50% of metastatic lesions). * Able to remain motionless for up to 30-60 minutes per scan. Exclusion Criteria: * Serum creatinine level \>150 μmol/L. * Hemoglobin level \<8.0 g/dL; white-cell count \< 2.0×109/L; platelet count \< 50×109/L; total bilirubin level \>3 times the upper limit of the normal range and serum albumin level \<2.0 g/dL. * Participants with Class 3 or 4 NYHA Congestive Heart Failure. * Participants with severe allergy, or hypersensitivity to radiographic contrast material. * Participants with claustrophobia. * Pregnant or lactating women.